With this background on the role of thrombin in tumor cell progression, there is need to address the question whether, by displacing thrombin from PAR‐1‐binding, dabigatran may be favorably exploited to uncouple thrombin‐driven mechanisms promoting tumor growth. The gene discussed is F2R; the disease is neoplasm.